We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ATRA market cap is 40.95M. The company's latest EPS is USD -47.9406 and P/E is -0.15.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.14M | 4.25M | 27.36M | 28.64M | 40.19M |
| Operating Income | -72.72M | -59.96M | -31.25M | -18.23M | -21.76M |
| Net Income | -69.8M | -60.45M | -31.75M | -19.05M | -21.91M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 20.34M | 63.57M | 8.57M |
| Operating Income | -295.68M | -309.05M | -340.46M | -280.51M | -276.01M |
| Net Income | -290.98M | -306.62M | -340.14M | -230M | -276.13M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 188.79M | 165.5M | 165.27M | 117.28M | 142.71M |
| Total Liabilities | 239.63M | 264.74M | 263.58M | 228.15M | 233.25M |
| Total Equity | -50.84M | -99.23M | -98.31M | -110.87M | -90.54M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 342.94M | 588.12M | 468.13M | 376.42M | 165.5M |
| Total Liabilities | 52.16M | 125.78M | 188.51M | 249.78M | 264.74M |
| Total Equity | 290.78M | 462.34M | 279.61M | 126.64M | -99.23M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -142.57M | -192.98M | -29.61M | -40.26M | -44.25M |
| Investing | 113.92M | 123.87M | 14.72M | 21.91M | 5.25M |
| Financing | 498k | 2.01M | 24.14M | 23.82M | 59.61M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -235.63M | -180.76M | -220.52M | -270.43M | -192.98M |
| Investing | 60.46M | -120.73M | 22.26M | 202.96M | 123.87M |
| Financing | 188.79M | 427.57M | 103.94M | 53.08M | 2.01M |
| Market Cap | 40.95M |
| Price to Earnings Ratio | -0.15 |
| Price to Sales Ratio | 4.79 |
| Price to Cash Ratio | 1.59 |
| Price to Book Ratio | -0.41 |
| Dividend Yield | - |
| Shares Outstanding | 5.76M |
| Average Volume (1 week) | 87.09k |
| Average Volume (1 Month) | 181.35k |
| 52 Week Change | -65.95% |
| 52 Week High | 23.4375 |
| 52 Week Low | 5.40 |
| Spread (Intraday) | 0.84 (10.71%) |
| Company Name | Atara Biotherapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.atarabio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
